Leveraging Site-selective Conjugation to Enable New Modalities & Groundbreaking Dual-Payload ADCs With Superior Characteristics & Activity
- Introducing the CysTyr™ Platform, dual-payload ADCs, and design parameters required for a successful dual-payload asset
- Demonstrating significantly superior activity for CatenaBio’s dual-payload ADC vs leading ADCs in CDX and PDX models
- Outlining CysTyr™ superior manufacturing resulting in unprecedented product purity and homogeneity with tunable DAR
- First report on NHP Tox trial for CATB-101 and significant improvements in therapeutic index vs leading ADCs